Antitumor activities of rauwolfia vomitoria extract and potentiation of carboplatin effects against ovarian cancer

Current Therapeutic Research - Clinical and Experimental

Volumn 75, Issue , 2013, Pages 8-14

  Yu, Jun ^a,b   Ma, Yan ^a,b   Drisko, Jeanne ^b   Chen, Qi ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Ovarian cancer; Plant extract; Rauwolfia vomitoria; Synergy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PLANT EXTRACT; RAUWOLFIA VOMITORIA EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; CELL GROWTH; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAUWOLFIA; RAUWOLFIA VOMITORIA; TUMOR VOLUME;

EID: 84890239490     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2013.04.001     Document Type: Article

References (56)

1. American Cancer Society. Cancer Facts and Figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed January 18, 2012.
2. Chen H., Hardy T.M., Tollefsbol T.O. Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2011, 2:67.
3. Buys S.S., Partridge E., Greene M.H., et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005, 193:1630-1639.
4. Beller U., Quinn M.A., Benedet J.L., et al. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S7-S27.
5. Monk B.J., Coleman R.L. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009, 19(Suppl 2):S63-S67.
6. Bellati F., Napoletano C., Ruscito I., et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs 2010, 28:887-894.
7. Campbell-Tofte J.I., Molgaard P., Josefsen K., et al. Randomized and double-blinded pilot clinical study of the safety and anti-diabetic efficacy of the Rauvolfia-Citrus tea, as used in Nigerian traditional medicine. J Ethnopharmacol 2011, 133:402-411.
8. Bisong S.A., Brown R., Osim E.E. Comparative effects of Rauwolfia vomitoria and chlorpromazine on locomotor behaviour and anxiety in mice. J Ethnopharmacol 2010, 132:334-339.
9. Bisong S., Brown R., Osim E. Comparative effects of Rauwolfia vomitoria and chlorpromazine on social behaviour and pain. N Am J Med Sci 2011, 3:48-54.
10. Bisong S.A., Brown R.E., Osim E.E. Comparative extrapyramidal effects of Rauwolfia vomitoria, chlorpromazine and reserpine in mice. J Nat Med 2013, 67:107-112.
11. Pesewu G.A., Cutler R.R., Humber D.P. Antibacterial activity of plants used in traditional medicines of Ghana with particular reference to MRSA. J Ethnopharmacol 2008, 116:102-111.
12. Kweifio-Okai G. Antiinflammatory activity of a Ghanaian antiarthritic herbal preparation: I. J Ethnopharmacol 1991, 33:263-267.
13. La Barre J., Castiau J. [Effect of reserpine-free Rauwolfia vomitoria extract on gastric motility in dogs]. C R Seances Soc Biol Fil 1957, 151:2222-2224.
14. La Barre J. Hypotensive effects of the completely dereserpinised extract of Rauwolfia vomitoria. Arzneimittelforschung 1973, 23:600-605.
15. Iwu M.M., Court W.E. Root alkaloids of Rauwolfia vomitoria afz. Planta Med 1977, 32:88-99.
16. Poisson J. [Research on the alkaloids of Rauwolfia vomitoria Afz. roots (Apocynacea)]. Trav Lab Matiere Med Pharm Galenique Fac Pharm Paris 1959, 44:2-118.
17. Plummer A.J., Earl A., Schneider J.A., et al. Pharmacology of Rauwolfia alkaloids, including reserpine. Ann N Y Acad Sci 1954, 59:8-21.
18. Schlittler E., Macphillamy H.B., Dorfman L., et al. Chemistry of Rauwolfia alkaloids, including reserpine. Ann N Y Acad Sci 1954, 59:1-7.
19. Wilkins R.W. Clinical usage of Rauwolfia alkaloids, including reserpine (serpasil). Ann N Y Acad Sci 1954, 59:36-44.
20. Poisson J., Le Hir A., Goutarel R., Janot M.M. [Isolation of reserpine from roots of Rauwolfia vomitoria Afz]. C R Hebd Seances Acad Sci 1954, 238:1607-1609.
21. Hariga M. [Preliminary trial of therapeutic use of reserpiline, a hypotensive extract of Rauwolfia vomitoria]. Brux Med 1959, 39:451-455.
22. Shamon S.D., Perez M.I. Blood pressure lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev 2009, CD007655.
23. Beljanski M., Beljanski M.S. Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology 1986, 43:198-203.
24. Bemis D.L., Capodice J.L., Gorroochurn P., et al. Anti-prostate cancer activity of a beta-carboline alkaloid enriched extract from Rauwolfia vomitoria. Int J Oncol 2006, 29:1065-1073.
25. Imai S., Kiyozuka Y., Maeda H., et al. Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. Oncology 1990, 47:177-184.
26. Isaiah A.M., Olawale O., Effiong E.E., et al. Vitamin e supplementation with rauwolfia vomitoria root bark extract improves hematological indices. N Am J Med Sci 2012, 4:86-89.
27. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 89:271-277.
28. Cole S.P. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 1986, 17:259-263.
29. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
30. Chou T., Rideout D., Chou J., Bertino J. Chemotherapeutic synergism, potentiation and antagonism. Encyclopedia Hum Biol 1991, 2:371-379.
31. Chou T., Talalay P. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. New Avenues Dev Cancer Chemother 1987, 8:37-64.
32. Eagle H., Foley G.E., Koprowski H., et al. Growth characteristics of virus-transformed cells. Maximum population density, inhibition by normal cells, serum requirement, growth in soft agar, and xenogeneic transplantability. J Exp Med 1970, 131:863-879.
33. Zeng G., Cai S., Liu Y., Wu G.J. METCAM/MUC18 augments migration, invasion, and tumorigenicity of human breast cancer SK-BR-3 cells. Gene 2012, 492:229-238.
34. Fu S., Hennessy B.T., Ng C.S., et al. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 2012, 126:47-53.
35. Weroha S.J., Oberg A.L., Ziegler K.L., et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 2011, 122:116-120.
36. Bell-McGuinn K.M., Matthews C.M., Ho S.N., et al. A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 2011, 121:273-279.
37. Beljanski M., Beljanski M.S. Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of beta-carboline class. Exp Cell Biol 1982, 50:79-87.
38. Chen F. JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res 2012, 72:379-386.
39. Chao M.P., Majeti R., Weissman I.L. Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer 2012, 12:58-67.
40. Dutta S., Chowdhury A.R., Srivastava S.K., et al. Evidence for Serpentine as a novel antioxidant by a redox sensitive HABP1 overexpressing cell line by inhibiting its nuclear translocation of NF-kappaB. Free Radic Res 2011, 45:1279-1288.
41. Rosengren A.H., Jokubka R., Tojjar D., et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010, 327:217-220.
42. NCCAM, Yohimbe. 2012. Accessed April 8, 2013. http://nccam.nih.gov/health/yohimbe.
43. Davies D.L., Shepherd M. Reserpine in the treatment of anxious and depressed patients. Lancet 1955, 269:117-120.
44. Wilkins R.W., Judson W.E., Stone R.W., et al. Reserpine in the treatment of hypertension; a note on the relative dosage and effects. N Engl J Med 1954, 250:477-478.
45. Chen G., Ensor C.R., Bohner B. A facilitation action of reserpine on the central nervous system. Proc Soc Exp Biol Med 1954, 86:507-510.
46. Belkin M., Hardy W.G. Effect of reserpine and chlorpromazine on sarcoma 37. Science 1957, 125:233-234.
47. Burton R.M., Goldin A., Humphreys S.R., Venditti J.M. Antileukemic action of reserpine. Science 1957, 125:156-157.
48. National Toxicology Program, HHS, 12th Report on Carcinogens, 2011. Accessed April 8, 2013. http://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/Reserpine.pdf.
49. Smirk F.H., Mc Q.E. Comparison of rescinnamine and reserpine as hypotensive agents. Lancet 1955, 269:115-116.
50. Gupta S., Khanna V.K., Maurya A., et al. Bioactivity guided isolation of antipsychotic constituents from the leaves of Rauwolfia tetraphylla L. Fitoterapia 2012, 83:1092-1099.
51. La Barre J., Hans M.J., Desmarez J.J. [Reserpiline, an hypotensive and non-tranquilizing alkaloid]. C R Seances Soc Biol Fil 1958, 152:533-534.
52. La Barre J., Lieber C.S., Castiau J. [Effect of reserpiline on gastric secretion and motility]. C R Seances Soc Biol Fil 1958, 152:532-533.
53. Maurya A., Gupta S., Srivastava S.K. Large-scale separation of antipsychotic alkaloids from Rauwolfia tetraphylla L. by pH-zone-refining fast centrifugal partition chromatography. J Sep Sci 2013, 36:407-413.
54. Chatterjee M.L., De M.S. Pharmacological action of ajmaline, the possible mechanism of its antiarrhythmic action, and its therapeutic possibilities. Nature 1963, 200:1067-1068.
55. Lenox H., Dick H., Mc C.E. Clinical pharmacologic observations of the effects of ajmaline in chronic atrial fibrillation. Clin Pharmacol Ther 1963, 4:315-320.
56. Duncan R.J., Nash C.B. Effects of the rauwolfia alkaloids, ajmaline, tetraphyllicine, and serpentine, on myocardial excitability. Arch Int Pharmacodyn Ther 1970, 184:355-361.